Most patients with systemic lupus erythematosus across a trio of anifrolumab trials demonstrated concordant outcomes on BILAG-based Composite Lupus Assessment and SLE Responder Index responses, according to data.
In addition, although a subgroup of patients with discordant responses was identified, they were overrepresented among those who received placebo in one of the trials. These participants demontrated lower baseline disease activity, joint counts and glucocorticoid tapering rates than those treated with anifrolumab (Saphnelo, AstraZeneca), the researchers wrote.
“As standard